Eugenia Lo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eugenia Lo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alfred Hubbard
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland
2 shared publications - Brook Jeang
Department of Population Health & Disease Prevention, UC Irvine Wen School of Population and Public Health , Irvine, California
2 shared publications - Daniel Janies
University of North Carolina at Charlotte
2 shared publications - Delenasaw Yewhalaw
School of Medical Laboratory Sciences, Institute of Health, Jimma University, Jimma P.O. Box 378, Ethiopia
2 shared publications - Edwin Solares
Halıcıoğlu Data Science Institute, University of California San Diego, La Jolla, CA, USA
2 shared publications - Elizabeth Hemming-Schroeder
Department of Microbiology, Immunology, and Pathology, Center for Vector-borne Infectious Diseases, Colorado State University, Fort Collins, United States of America
2 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (3) , e681-e689
PvGAP: Development of a Globally Applicable, Highly Multiplexed Microhaplotype Amplicon Panel for Plasmodium vivax
Background: Plasmodium vivax malaria research has yet to fully benefit from advances in genomic surveillance that have revolutionized P. falciparum epidemiology. Closing this gap will enable monitoring the spread of drug resistance, classifying infections as local or imported, and distinguishing reinfection, recrudescence, and relapse. To achieve these objectives, microhaplotype marker panels that allow powerful genotyping of polyclonal infections are needed. Methods: We designed a globally applicable amplicon panel for P. vivax (PvGAP), selecting targets based on both genetic diversity and distance to maximize discriminatory capability between geographic regions. We evaluated this panel with field samples from Ethiopia and in silico using whole genomes from the MalariaGEN Pv4 database. Results: PvGAP has 80 high-diversity targets suitable for population genomics and 8 targets of epidemiological interest, such as putative markers of drug resistance. We demonstrate robust amplification with field data and competitive accuracy for relatedness inference in 3 disparate geographic regions. Conclusions: PvGAP joins existing P. vivax panels as a cost-effective and practical option for genomic epidemiology of this neglected disease. It will support drug resistance surveillance and discrimination of local and imported cases, and it may aid in separating reinfection, recrudescence, and relapse in therapeutic efficacy studies, all critical needs of National Malaria Control Programs.
- 21 May 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (3) , e681-e689
Open AccessPvGAP: Development of a Globally Applicable, Highly Multiplexed Microhaplotype Amplicon Panel for Plasmodium vivax
Background: Plasmodium vivax malaria research has yet to fully benefit from advances in genomic surveillance that have revolutionized P. falciparum epidemiology. Closing this gap will enable monitoring the spread of drug resistance, classifying infections as local or imported, and distinguishing reinfection, recrudescence, and relapse. To achieve these objectives, microhaplotype marker panels that allow powerful genotyping of polyclonal infections are needed. Methods: We designed a globally applicable amplicon panel for P. vivax (PvGAP), selecting targets based on both genetic diversity and distance to maximize discriminatory capability between geographic regions. We evaluated this panel with field samples from Ethiopia and in silico using whole genomes from the MalariaGEN Pv4 database. Results: PvGAP has 80 high-diversity targets suitable for population genomics and 8 targets of epidemiological interest, such as putative markers of drug resistance. We demonstrate robust amplification with field data and competitive accuracy for relatedness inference in 3 disparate geographic regions. Conclusions: PvGAP joins existing P. vivax panels as a cost-effective and practical option for genomic epidemiology of this neglected disease. It will support drug resistance surveillance and discrimination of local and imported cases, and it may aid in separating reinfection, recrudescence, and relapse in therapeutic efficacy studies, all critical needs of National Malaria Control Programs.
- Open Access
PvGAP: Development of a globally-applicable, highly-multiplexed microhaplotype amplicon panel for Plasmodium vivax
Background: Plasmodium vivax malaria research has yet to fully benefit from the advances in genomic surveillance that have revolutionized P. falciparum epidemiology. Closing this gap is critical because genomic tools are necessary to monitor the spread of drug resistance, classify infections as local or imported, and distinguish reinfection, recrudescence, and relapse. To achieve these objectives, microhaplotype marker panels that allow powerful genotyping of polyclonal infections are needed. Methods: We designed a Globally-applicable Amplicon Panel for P. vivax (PvGAP), selecting targets based on both genetic diversity and genetic distance from each other to maximize discriminatory capability between geographic regions. We evaluated this panel with field samples from Ethiopia and in silico using whole genomes from the MalariaGEN Pv4 database. Results: PvGAP has 80 high diversity targets suitable for population genomics and eight targets of specific epidemiological interest, such as putative markers of drug resistance. We demonstrate PvGAP achieves robust amplification with field data and that it provides competitive accuracy for relatedness inference in three disparate geographic regions. Conclusions: PvGAP joins existing P. vivax panels as a cost effective and practical option for genomic epidemiology of this neglected disease. It will support drug resistance surveillance, discrimination of local and imported cases, and it may aid in separating reinfection, recrudescence, and relapse in therapeutic efficacy studies, all critical needs of National Malaria Control Programs.
Open AccessPvGAP: Development of a globally-applicable, highly-multiplexed microhaplotype amplicon panel for Plasmodium vivax
Background: Plasmodium vivax malaria research has yet to fully benefit from the advances in genomic surveillance that have revolutionized P. falciparum epidemiology. Closing this gap is critical because genomic tools are necessary to monitor the spread of drug resistance, classify infections as local or imported, and distinguish reinfection, recrudescence, and relapse. To achieve these objectives, microhaplotype marker panels that allow powerful genotyping of polyclonal infections are needed. Methods: We designed a Globally-applicable Amplicon Panel for P. vivax (PvGAP), selecting targets based on both genetic diversity and genetic distance from each other to maximize discriminatory capability between geographic regions. We evaluated this panel with field samples from Ethiopia and in silico using whole genomes from the MalariaGEN Pv4 database. Results: PvGAP has 80 high diversity targets suitable for population genomics and eight targets of specific epidemiological interest, such as putative markers of drug resistance. We demonstrate PvGAP achieves robust amplification with field data and that it provides competitive accuracy for relatedness inference in three disparate geographic regions. Conclusions: PvGAP joins existing P. vivax panels as a cost effective and practical option for genomic epidemiology of this neglected disease. It will support drug resistance surveillance, discrimination of local and imported cases, and it may aid in separating reinfection, recrudescence, and relapse in therapeutic efficacy studies, all critical needs of National Malaria Control Programs.